Brain-computer interface "unicorn" Qiangnao Technology completes 2 billion yuan financing, second only to Musk's Neuralink in scale
Qiangnao Technology's recent financing of nearly 2 billion yuan was backed by top financial capital and industry giants such as Lens, marking that brain-computer interface technology has crossed the laboratory stage and is accelerating towards large-scale production and commercialization. As a result, the capital market reacted strongly, with related concept stocks continuing to rise, and the industry is rapidly transitioning from laboratory research and development to mass production and commercialization
Leading company in the brain-computer interface field, QiangNai Technology, recently completed financing of approximately 2 billion RMB, setting the second-largest financing record globally in this sector, after Neuralink, and marking a strong endorsement from top capital for the commercialization process of this cutting-edge technology.
According to a report by The Paper on January 6, this round of financing features a luxurious lineup of investors, led by well-known institutions IDG and Huaden International, and includes strategic investors from the supply chain such as Lens Technology and Weir Shares. This massive investment comes at a time when the global brain-computer interface sector is gaining momentum, indicating that market confidence in the technology's transition from laboratory to large-scale application is rapidly increasing.
Driven by this news and Elon Musk's statement that Neuralink will start large-scale production in 2026, the capital market reacted strongly. Since the market opened in 2026, brain-computer interface concept stocks have performed robustly, with multiple stocks such as BeiYikang and Sanbo Brain Science hitting the daily limit, and others like Sainuo Medical, Guanhao Biological, Aipeng Medical, Meihao Medical, Xiangyu Medical, and Lepu Medical also reaching the 20% daily limit. Investors are reassessing the commercial prospects and valuation space of this key technology field.
The deep involvement of supply chain giants like Lens Technology further validates the trend of the industry transitioning from R&D to mass production. As the exclusive contractor for QiangNai Technology's core hardware modules, Lens Technology stated that it is actively seeking more collaborations based on its precision manufacturing capabilities, indicating that the upstream and downstream of the supply chain are accelerating integration.
Top Capital and Industry Giants Join Forces to Invest
According to media reports, this round of financing has gathered dual support from financial investors and industrial capital. The investors include IDG Capital and Huaden International, founded by Intel CEO Chen Liwu. Additionally, strategic investors such as supply chain giants Lens Technology, Lingyi Intelligent Manufacturing, Weir Shares, Runze Technology, Huazhu Group, and TAL Education Group are also included. The list also features top family offices from Hong Kong and the United States.
The deep binding of the supply chain is a major highlight of this round of financing. Lens Technology confirmed in a response to investor inquiries on January 6 that the company is a strategic investor in QiangNai Technology and has exclusively undertaken the mass production of its core hardware modules. In November 2025, Lens Technology, together with QiangNai Technology, donated a large number of intelligent bionic limbs to the Hunan Provincial Disabled Persons' Federation, with all core modules sourced from Lens's production line. This "capital + manufacturing" cooperation model provides supply chain assurance for the large-scale implementation of brain-computer interface products.
Global Competitive Landscape Benchmarking Neuralink
As a "unicorn" in the brain-computer interface field, QiangNai Technology is listed alongside companies like DeepSeek and Yushu Technology as part of the "Six Little Dragons of Hangzhou." The company focuses on the R&D of brain-computer interface products and is one of the very few globally to achieve large-scale mass production of products, having obtained both FDA certification in the United States and CE certification in Europe, with R&D investment ranking among the top in the industry The catalyst for this round of market trends comes from the latest developments of its main competitor Neuralink. On January 1st, Musk announced that Neuralink would start large-scale production of devices in 2026 and advance fully automated surgical solutions; then on January 3rd, he expressed confidence in helping paralyzed individuals regain full body function. These two significant pieces of information validated the technical feasibility and directly drove stocks of related companies such as BeiYikang, XiangYu Medical, and MeiHao Medical to consecutive limit-ups after the market opened in 2026.
QiangNai Technology was founded in 2015 by Harvard alumnus Han Bicheng, focusing on non-invasive brain-machine interfaces. By establishing signal pathways between the brain and external devices, it provides solutions for rehabilitation of disabled individuals and treatment of brain diseases. Han Bicheng previously stated that brain-machine interfaces are transitioning from laboratory research to becoming key technologies that impact daily life, with the potential to make the human brain "transparent" in the future.
Commercialization and IPO Expectations
In terms of commercial applications, QiangNai Technology's core product, the "Super Sensor," can detect weak brain electrical signals without the need for craniotomy, converting them into neural signals to control external devices. Currently, its products can help individuals with limb disabilities achieve functions such as running and performing high-difficulty sports. Han Bicheng proposed that within the next 5 to 10 years, the plan is to help 1 million individuals with limb disabilities regain mobility and assist 10 million patients with Alzheimer's, autism, and insomnia in their rehabilitation.
Regarding the next steps in the capital market, according to previous reports from Bloomberg, QiangNai Technology may conduct an initial public offering (IPO) in Hong Kong or mainland China. Insiders revealed to the media that the company has begun preparing listing documents, but the specific location and details have not yet been finalized, and related discussions remain full of uncertainties.
As China increases its investment in the field of brain science and brain-machine interfaces, known as the "Brain Project," and with financing in place for leading companies like QiangNai Technology, this sector is accelerating into a new phase of technological realization and commercial explosion
